Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 353

Sort by

Sort Order Select

Journal Articles

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Karen Dybkær, PhD, Hanne Due, MSc, Rasmus Froberg Brøndum, PhD, Ken H. Young, MD PhD, Martin Bøgsted, PhD

Blood (2019) 134 (Supplement_1): 1623.

https://doi.org/10.1182/blood-2019-122351

Published: 2019

Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1863.

https://doi.org/10.1182/blood-2019-131515

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2019) 134 (Supplement_1): 1941.

https://doi.org/10.1182/blood-2019-121973

Published: 2019

Journal Articles

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Muneyoshi Futami, MD PhD, Keisuke Suzuki, MS, Satomi Kato, BS, Yoshio Tahara, MS, Yoichi Imai, MD PhD, Takayuki Mimura, PhD, Yoshihiro Watanabe, PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 2067.

https://doi.org/10.1182/blood-2019-129601

Published: 2019

Journal Articles

Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) As Allogeneic Cancer Immunotherapy

Srinivas Somanchi, PhD, Xuan Guo, PhD, Shuyang He, PhD, Rohit Mathur, PhD, Andrea Difiglia, BS, Hemlata Rana, MS, Weifang Ling, PhD, James Edinger, PhD, Gunnar F. Kaufmann, PhD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 2070.

https://doi.org/10.1182/blood-2019-129539

Published: 2019

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

Journal Articles

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Eduardo Huarte, PhD, Roddy S O'Connor, PhD, Melissa Parker, Taisheng Huang, Michael C. Milone, Paul Smith

Blood (2019) 134 (Supplement_1): 1934.

https://doi.org/10.1182/blood-2019-128288

Published: 2019

Journal Articles

Human Interleukin 15 (IL15) Humanized NCG Mice Support the Human Natural Killer Cells Reconstitution and Development

Cunxiang Ju, PhD, Mingkun Zhang, Dan Wu, Jing Tang, PhD, Shuai Li, Jing Zhao, PhD, Demin Wang, PhD, Xiang Gao, PhD

Blood (2019) 134 (Supplement_1): 4871.

https://doi.org/10.1182/blood-2019-123661

Published: 2019

Journal Articles

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Martin Dreyling, MD, Marco Ladetto, MD, Jeanette K. Doorduijn, MD PhD, Eva Gine, MD, Mats Jerkeman, MD Professor, Ulrich Mey, MD, Michal Szymczyk, MD, Martin Hutchings, MD PhD, Arne Kolstad, MD PhD, Gregor Verhoef, MD PhD, Marek Trneny, MD prof, Maria Gomes da Silva, MD, Christiane Pott, MD PhD, Wolfram Klapper, Michael Unterhalt, PhD, Eva Hoster, PhD

Blood (2019) 134 (Supplement_1): 2816.

https://doi.org/10.1182/blood-2019-127863

Published: 2019

Journal Articles

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Meng Wang, BS, Stefan M Lundh, BS, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 681.

https://doi.org/10.1182/blood-2019-122063

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Andrew Dunbar, MD, Kelly Bolton, MD PhD, Sean M. Devlin, PhD, Francisco Sanchez-Vega, PhD, Jianjiong Gao, PhD, Jodi V. Mones, MD, Jonathan M. Wills, BA, Daniel Kelly, MS, Mirko Farina, MD, Sirish Kishore, MD, Krishna Juluru, MD, Neil Iyengar, MD, David M. Hyman, MD, Ahmet Zehir, PhD, Wungki Park, MD, Alok A Khorana, MD, Gerald A. Soff, MD, Simon Mantha, MDMPH

Blood (2019) 134 (Supplement_1): 633.

https://doi.org/10.1182/blood-2019-124242

Published: 2019

Journal Articles

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Huang Zhu, PhD, Robert Blum, Zhengming Wu, Zhipeng Meng, PhD, Kun-Liang Guan, PhD, Dan S Kaufman, MD PhD

Blood (2019) 134 (Supplement_1): 619.

https://doi.org/10.1182/blood-2019-124446

Published: 2019

Journal Articles

Recipient Signaling through the Cannabinoid Type 2 Receptor Regulates IL-6 Independent Neuroinflammation during Graft Versus Host Disease

Alison Moe, PhD, Garrett Sauber, BS, Vivian Zhou, PhD, Anissa Lapitz, BS, Cecilia Hillard, PhD, William R. Drobyski, MD

Blood (2019) 134 (Supplement_1): 195.

https://doi.org/10.1182/blood-2019-122746

Published: 2019

Journal Articles

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Fiona Brown, BS, Yang Zhang, PhD, Claire Hinterschied, Alexander Prouty, BS, Shelby Sloan, BS, JoBeth Helmig-Mason, Msc, Ji Hyun Chung, PhD, Kris Vaddi, PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Lapo Alinari, MD PhD, Peggy Scherle, PhD, Rosa Lapalombella, PhD, Jihye Paik, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 302.

https://doi.org/10.1182/blood-2019-130797

Published: 2019

Journal Articles

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, MD Professor, Sverker Hasselblom, Björn E Wahlin, MD PhD, Per-Ola Andersson, MD PhD, Karin E. Smedby, MD PhD

Blood (2019) 134 (Supplement_1): 399.

https://doi.org/10.1182/blood-2019-122014

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

NARROW

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) As Allogeneic Cancer Immunotherapy

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Human Interleukin 15 (IL15) Humanized NCG Mice Support the Human Natural Killer Cells Reconstitution and Development

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Recipient Signaling through the Cannabinoid Type 2 Receptor Regulates IL-6 Independent Neuroinflammation during Graft Versus Host Disease

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only